Eric S Orman1, Marwan Ghabril2, Thomas W Emmett3, Naga Chalasani2. 1. Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, Indiana, USA. esorman@iu.edu. 2. Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, Indiana, USA. 3. Ruth Lilly Medical Library, Indiana University School of Medicine, Indianapolis, Indiana.
Abstract
BACKGROUND: Hospital readmission is a significant problem for patients with complex chronic illnesses such as liver cirrhosis. PURPOSE: We aimed to describe the range of readmission risk in patients with cirrhosis and the impact of the model for end-stage liver disease (MELD) score. DATA SOURCES: We conducted a systematic review of studies identified in Ovid MEDLINE, PubMed, EMBASE, CINAHL, the Cochrane Library, Scopus, Google Scholar, and ClinicalTrials.gov from 2000 to May 2017. STUDY SELECTION: We examined studies that reported early readmissions (up to 90 days) in patients with cirrhosis. Studies were excluded if they did not examine the association between readmission and at least 1 variable or intervention. DATA EXTRACTION: Two reviewers independently extracted data on study design, setting, population, interventions, comparisons, and detailed information on readmissions. DATA SYNTHESIS: Of the 1363 records reviewed, 26 studies met the inclusion and exclusion criteria. Of these studies, 21 were retrospective, and there was significant variation in the inclusion and exclusion criteria. The pooled estimate of 30-day readmissions was 26%(95% confidence interval [CI], 22%-30%). Few studies examined readmission preventability or the relationship between readmissions and social determinants of health. Reasons for readmission were highly variable. An increased MELD score was associated with readmissions in most studies. Readmission was associated with increased mortality. CONCLUSIONS: Hospital readmissions frequently occur in patients with cirrhosis and are associated with liver disease severity. The impact of functional and social factors on readmissions is unclear.
BACKGROUND: Hospital readmission is a significant problem for patients with complex chronic illnesses such as liver cirrhosis. PURPOSE: We aimed to describe the range of readmission risk in patients with cirrhosis and the impact of the model for end-stage liver disease (MELD) score. DATA SOURCES: We conducted a systematic review of studies identified in Ovid MEDLINE, PubMed, EMBASE, CINAHL, the Cochrane Library, Scopus, Google Scholar, and ClinicalTrials.gov from 2000 to May 2017. STUDY SELECTION: We examined studies that reported early readmissions (up to 90 days) in patients with cirrhosis. Studies were excluded if they did not examine the association between readmission and at least 1 variable or intervention. DATA EXTRACTION: Two reviewers independently extracted data on study design, setting, population, interventions, comparisons, and detailed information on readmissions. DATA SYNTHESIS: Of the 1363 records reviewed, 26 studies met the inclusion and exclusion criteria. Of these studies, 21 were retrospective, and there was significant variation in the inclusion and exclusion criteria. The pooled estimate of 30-day readmissions was 26%(95% confidence interval [CI], 22%-30%). Few studies examined readmission preventability or the relationship between readmissions and social determinants of health. Reasons for readmission were highly variable. An increased MELD score was associated with readmissions in most studies. Readmission was associated with increased mortality. CONCLUSIONS: Hospital readmissions frequently occur in patients with cirrhosis and are associated with liver disease severity. The impact of functional and social factors on readmissions is unclear.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Cynthia Feltner; Christine D Jones; Crystal W Cené; Zhi-Jie Zheng; Carla A Sueta; Emmanuel J L Coker-Schwimmer; Marina Arvanitis; Kathleen N Lohr; Jennifer C Middleton; Daniel E Jonas Journal: Ann Intern Med Date: 2014-06-03 Impact factor: 25.391
Authors: Amit G Singal; Robert S Rahimi; Christopher Clark; Ying Ma; Jennifer A Cuthbert; Don C Rockey; Ruben Amarasingham Journal: Clin Gastroenterol Hepatol Date: 2013-04-13 Impact factor: 11.382
Authors: Elliot B Tapper; Daniel Finkelstein; Murray A Mittleman; Gail Piatkowski; Matthew Chang; Michelle Lai Journal: Clin Gastroenterol Hepatol Date: 2015-09-25 Impact factor: 11.382
Authors: K J Fagan; E Y Zhao; L U Horsfall; B J Ruffin; M S Kruger; S M McPhail; P O'Rourke; E Ballard; K M Irvine; E E Powell Journal: Intern Med J Date: 2014-09 Impact factor: 2.048
Authors: Jejo D Koola; Sam B Ho; Aize Cao; Guanhua Chen; Amy M Perkins; Sharon E Davis; Michael E Matheny Journal: Dig Dis Sci Date: 2019-09-17 Impact factor: 3.199
Authors: Hani Shamseddeen; Kavish R Patidar; Marwan Ghabril; Archita P Desai; Lauren Nephew; Sandra Kuehl; Naga Chalasani; Eric S Orman Journal: Am J Med Date: 2020-05-29 Impact factor: 4.965
Authors: Adeyinka Charles Adejumo; Donghee Kim; Umair Iqbal; Eric R Yoo; Brian C Boursiquot; George Cholankeril; Robert J Wong; Paul Y Kwo; Aijaz Ahmed Journal: J Palliat Med Date: 2019-08-09 Impact factor: 2.947
Authors: Lindsay Yoder; Andrea Mladenovic; Francis Pike; Raj Vuppalanchi; Haleigh Hanson; Laura Corbito; Archita P Desai; Naga Chalasani; Eric S Orman Journal: Am J Med Date: 2021-10-14 Impact factor: 4.965
Authors: Adeyinka C Adejumo; George Cholankeril; Umair Iqbal; Eric R Yoo; Brian C Boursiquot; Waldo C Concepcion; Donghee Kim; Aijaz Ahmed Journal: Dig Dis Sci Date: 2019-08-01 Impact factor: 3.199
Authors: John H Holden; Hani Shamseddeen; Amy W Johnson; Benjamin Byriel; Kavitha Subramoney; Yao-Wen Cheng; Akira Saito; Marwan Ghabril; Naga Chalasani; Greg A Sachs; Eric S Orman Journal: J Palliat Med Date: 2020-02-24 Impact factor: 2.947